After the Pandemic, the 1 Healthcare Stock I’m Buying Today

VieMed Healthcare Inc. (TSX:VMD) is a healthcare stock I’m still bullish on, as we move into the month of May.

| More on:
healthcare pharma

Image source: Getty Images

The severity of the COVID-19 pandemic became apparent in North America in March 2020. That month saw big decision makers in the public and private sphere take unprecedented steps to control the spread of the virus. Moreover, global markets reacted violently, as the pandemic forced mass closures in the private and public sphere. While many equities plunged into the red, there were other stocks that thrived in the face of the most significant global pandemic since the outbreak of the flu in 1918.

Today, I want to zero in on one healthcare stock that thrived during the health crisis and can reward investors even more going forward. Let’s dive in!

What healthcare stocks performed well during the COVID-19 pandemic?

Healthcare stocks do not necessarily behave as defensive investment vehicles during a global pandemic. Bausch Health Companies, the Laval-based company that develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products, saw its momentum dashed in the face of the pandemic. Its shares plunged sharply in late February 2020 and took nearly an entire year to fully recover in 2021.

Northwest Healthcare REIT is a real estate investment trust (REIT) that owns and operates a global portfolio of high-quality healthcare real estate. Shares of this REIT also suffered a harsh price dip in February and March of 2020. However, this stock would become more attractive to investors, as the pandemic pressed forward.

VieMed Healthcare (TSX:VMD) is the healthcare stock I want to focus on today. This Louisiana-based company provides in-home durable medical equipment (DME) and post-acute respiratory healthcare services to patients in the United States. VieMed stock did suffer a dip in the middle of March 2020. However, it had recovered and posted a 52-week high by the middle of May. Its stock is up 10% month over month as of close on April 28. Shares have climbed 42% so far in 2023. Investors can see more of its recent and past performance by playing with the interactive price chart below.

Here’s why I’m still bullish on this healthcare stock in May 2023

Precedence Research last valued the global medical equipment market at US$35.7 billion in 2021. The report projected that this market would reach US$62.1 billion by 2030. That would represent a compound annual growth rate (CAGR) of 6.3% from 2022 through to the end of the forecast period. Moreover, the COVID-19 pandemic put a spotlight on long-term respiratory illnesses. Spherical Insights valued the global acute respiratory distress syndrome market at US$980 million in 2021. That researcher projected this market would reach $2.13 billion by 2030, representing a CAGR of 7.9%.

This healthcare stock boasts exposure to very promising industries in the space. VieMed Healthcare released its final batch of fiscal 2022 earnings on March 2, 2023. The company posted net revenues of $138 million for the full year — up from $117 million in fiscal 2021. Meanwhile, gross profit rose to $84.6 million compared to $73.4 million in the previous year.

VieMed is in a great spot as Chief Executive Officer Casey Hoyt boasted that “The healthcare market and regulatory environment are stabilizing.” Hoyt went on to say, “…we are at an inflection point of opportunity for both organic and inorganic growth.” That is worth getting excited about.

Should you buy VieMed Healthcare today?

Shares of this healthcare stock are trading in very favourable value territory compared to VieMed’s industry peers. Moreover, the company is on track for strong earnings growth going forward. This is a stock worth snatching up, as it continues its hot streak in the spring of 2023.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned. The Motley Fool recommends NorthWest Healthcare Properties Real Estate Investment Trust. The Motley Fool has a disclosure policy.

More on Investing

Double exposure of a businessman and stairs - Business Success Concept
Dividend Stocks

Is Exchange Income Stock a Buy?

Even within an industry, some stocks might be worth considering in certain market conditions, while others may be avoided.

Read more »

online shopping
Tech Stocks

Shopify Stock Rose 22% Last Month: Is it Still a Buy in June 2023?

Shopify (TSX:SHOP) stock rose 22% in the last month but is down from 52-week highs. So, is it time to…

Read more »

Dividend Stocks

2 Top Canadian Value Stocks in June 2023

Canadian Imperial Bank of Commerce (CIBC) stock is a compelling buy in June, and so is this Canadian REIT.

Read more »

Illustration of bull and bear
Dividend Stocks

2 Cyclical Stocks to Buy Before the Next Bull Market

The TSX index has been cyclical in the past 12 months, with neither a bearish nor a bullish trend fully…

Read more »

Hand arranging wood block stacking as step stair with arrow up.

3 Top Canadian Growth Stocks for June 2023

These growth stocks might be up in 2023, but each provides a strong opportunity both for recovery in 2023, and…

Read more »

calculate and analyze stock
Dividend Stocks

Dividend Investors: 4 Canadian Stocks for Many Decades of Payouts

Are you looking for decades of dividends? These four top Canadian income stocks are ideal for steady compounding returns.

Read more »

Paper airplanes flying on blue sky with form of growing graph

$1,000 Invested in Bombardier Stock 10 Years Back Would Be Worth This Much Today

Bombardier stock is down over 50% in the last 10 years but has more than tripled since June 2020. Should…

Read more »

railroad with nature background
Dividend Stocks

CNR Stock Sagged 2% Last Month: Should You Buy the Dip?

CNR stock has surged 1,760% since June 2003 after adjusting for dividends. But is the TSX blue-chip stock a buy…

Read more »